Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 2 1Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Carcinoma, Renal Cell 5Neuroendocrine Tumors 3Neoplasms 3Tuberous Sclerosis 2Kidney Neoplasms 2Breast Neoplasms 2Angiomyolipoma 2Waldenstrom Macroglobulinemia 1Skin Neoplasms 1Skin Diseases 1Pancreatic Neuroendocrine Tumors 1Neoplasms, Plasma Cell 1Neoplasm Metastasis 1Lymphoma 1Lymphangioleiomyomatosis 1Lung Neoplasms 1Leukemia, Lymphocytic, Chronic, B-Cell 1Carcinoma, Large Cell 1Carcinoma, Hepatocellular 1Carcinoid Tumor 1Breast Diseases 1

Interventions

fludarabine phosphate 1fludarabine 1Thiotepa 1Sirolimus 1Radiotherapy 1Prednisone 1Influenza Vaccines 1Fluzone High-Dose 1Filgrastim 1Everolimus 1Cyclophosphamide 1Busulfan 1Antilymphocyte Serum 113-valent pneumococcal vaccine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Neoplasms, Plasma Cell × Everolimus × Clear all
NCT07426484 2026-02-23

Cosibelimab for CSCC in Patients With Kidney Transplant or Hematologic Malignancy

Dana-Farber Cancer Institute

Phase 4 Not yet recruiting
80 enrolled
DermatologicLymphoidOther hematologic neoplasmPlasma cell

Lymphoma, Waldenstrom Macroglobulinemia, Skin Neoplasms, Leukemia, Lymphocytic, Chronic, B-Cell, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡